

## **Radiosynthesis of [ $^{11}\text{C}$ ]-N-Methylacyclovir**

Alan A. Wilson, Peter S. Conti, Robert F. Dannals,  
Hayden T. Ravert, and Henry N. Wagner, Jr.

Divisions of Nuclear Medicine and Radiation Health Science  
The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2179


### **Summary**

A selective and potent analogue of the anti-herpes agent acyclovir has been labelled with  $^{11}\text{C}$  in good yield and at high specific activities. 1- [ $^{11}\text{C}$ ]-Methyl-9-[(2-hydroxyethoxy)methyl]guanine may be useful for detecting HSV encephalitis using positron emission tomography.

**Key Words:** carbon-11, acyclovir, HSV encephalitis, PET

Following the discovery that the guanosine analogue 9-[(2-hydroxyethoxy)-methyl]guanine (acyclovir) was a potent and selective anti-herpes drug (1), many derivatives have been synthesized and tested as anti-viral agents (2, 3). One of these, 1-methyl-9-[(2-hydroxyethoxy)-methyl]guanine (methylacyclovir, MAC), has demonstrated equivalent efficacy and selectivity to acyclovir in inhibiting HSV-1 and HSV-2 herpes simplex viruses (2) and is suitable for labelling with the positron emitting radionuclide,  $^{11}\text{C}$ . The development of radiolabelled antiviral agents which selectively localize in infected cells may permit the non-invasive detection of HSV encephalitis using positron emission tomography (PET), and perhaps preclude the need for invasive tissue biopsy for definitive diagnosis. We report here the radiosynthesis and purification of [ $^{11}\text{C}$ ]-MAC (4) which may prove to be a useful radiotracer for such studies.

Unlabelled MAC was prepared by modification of a literature procedure (2). Using acyclovir as precursor, the radiosynthesis of [ $^{11}\text{C}$ ]-MAC (Scheme 1) is a facile procedure. Treatment of the conjugate base of acyclovir, generated at  $-70\text{ }^\circ\text{C}$  in DMF with tetrabutylammonium hydroxide, with [ $^{11}\text{C}$ ]-iodomethane effected [ $^{11}\text{C}$ ]-methylation to give the desired product. In the absence of added base methylation occurs more slowly and primarily at  $\text{N}_7$  rather than the desired  $\text{N}_1$  (2). In consideration for the rapid decay of  $^{11}\text{C}$  ( $t_{1/2}$  20.3 min), the reaction was conducted at  $40\text{ }^\circ\text{C}$  to ensure completion in five min.



Scheme 1.

Rapid purification of [ $^{11}\text{C}$ ]-MAC was achieved by semi-preparative HPLC. Upon isolation of the product-containing fraction from the HPLC, the product was formulated suitable for animal or human studies. The average ( $n = 6$ ) time of synthesis was 21 min from end-of-bombardment to formulated product ready for biological studies. The average isolated radiochemical yield was 20% based on [ $^{11}\text{C}$ ]-iodomethane (uncorrected for decay) and the average specific activity was 955  $\text{mCi}/\mu\text{mole}$  at end-of synthesis. Radiochemical purities were greater than 98%.

### Experimental

NMR spectra were obtained on an IBM NR/80 using  $(\text{CH}_3)_4\text{Si}$  as an internal standard. DMF was stirred overnight with BaO, then distilled under reduced pressure from BaO. Purification and analyses of radioactive mixtures by HPLC were performed with a previously described system (5). Peak areas were measured using Hewlett-Packard 3390A recording integrators. Isolated radiochemical yields were determined with a dose-calibrator (Capintec CRC-12). All formulated radiochemical preparations tested sterile and pyrogen-free.

**N-Methylacyclovir (MAC)** A solution of 9-[(2-hydroxyethoxy)methyl]guanine (50 mg, 0.21 mmol) and tetrabutylammonium hydroxide (0.22 mL of a 1M solution in methanol) in DMF (4.6 mL) was stirred at room temperature whilst a solution of iodomethane (32.6 mg, 0.23 mmol) in DMF (150  $\mu$ L) was added over 5 min. The mixture was stirred for a further 20 min and the crude product collected by vacuum filtration upon precipitation with ether (50 mL). Recrystallization from water afforded pure product as white crystals (27 mg, 54%); mp 233-237 °C (dec.) (lit. 253 °C (2)). The <sup>1</sup>H NMR spectrum (in DMSO-d<sub>6</sub>) was nearly identical to that previously reported (2).

**[<sup>14</sup>C]-MAC** [<sup>14</sup>C]-Iodomethane, produced as previously described (6), was swept by a stream of nitrogen into a freshly prepared solution of acyclovir (1-1.2 mg, 4.3-5.1  $\mu$ mol) in DMF (50  $\mu$ L) containing 0.5 equivalents of aqueous tetrabutylammonium hydroxide (0.4 M) at -70 °C. The reaction mixture was heated in a water bath at 40 °C for 5 min then quenched with 0.1N ammonium formate (900  $\mu$ L) and injected onto the HPLC column (Alltech Econosil C<sub>18</sub>; 25cm x 10mm; 5% CH<sub>3</sub>CN:95% H<sub>2</sub>O + 0.1N NH<sub>4</sub>HCO<sub>2</sub> 10 mL/min; k'<sub>MAC</sub> = 4.5). The appropriate fraction was collected, volatiles removed by rotary evaporation under vacuum, and the residue taken up in sterile pyrogen-free saline (7 mL). After filtration through a Millipore filter (0.22  $\mu$ ) the solution was adjusted to physiological pH by addition of sterile pyrogen-free 1N sodium bicarbonate. The radiochemical purity and specific activity were determined by analytical HPLC (7) (Alltech Econosil C<sub>18</sub>; 25cm x 4.5mm; 5% CH<sub>3</sub>CN:95% H<sub>2</sub>O + 0.1N NH<sub>4</sub>HCO<sub>2</sub> 4 mL/min; k'<sub>MAC</sub> = 3.5).

### Acknowledgements

The authors thank Mr. Robert Smoot for his assistance with cyclotron operations and radiochemical syntheses. This work was supported in part by grant number NS-15080 from the U.S. Public Health Service.

### References

1. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., and Schaeffer J. H. - Proc. Natl. Acad. Sci. USA **74**: 5716 (1977).
2. Boryski J., Golankiewicz B., and De Clercq E. - J. Med. Chem. **31**: 1351 (1988).

3. Saxena N. K., Hagenow B. M., Genzlinger G., Turk S. R., Drach J. C., and Townsend L. B. - *J. Med. Chem.* 31: 1501 (1988).
4. Wilson A. A., Conti P. S., Dannals R. F., Ravert H. T., and Wagner H. N., Jr. - *J. Nucl. Med.* 30: P929 (1989).
5. Dannals R. F., Ravert H. T., Frost J. J., Wilson A. A., Burns H. D., and Wagner H. N., Jr. - *Int. J. Appl. Radiat. Isot.* 36: 303 (1985).
6. Dannals R. F., Ravert H. T., Wilson A. A., and Wagner H. N., Jr. - *Appl. Radiat. Isot. Int. J. Appl. Instrum. Part A* 37: 433 (1986).
7. Wilson A. A., Dannals R. F., Ravert H. T., Frost J. J., and Wagner H. N., Jr. - *J. Med. Chem.* 32: 1057 (1989).